Head and neck cancer is the seventh most common type of cancer worldwide and comprise
of a diverse group of tumours affecting the upper aerodigestive tract. Although many different …

The main breakthrough in tumor immunotherapy was the discovery of immune checkpoint
(IC) proteins, which act as a potent suppressor of the immune system by a myriad of …

Background Chemoradiotherapy is the standard of care for unresected locally advanced
squamous cell carcinoma of the head and neck. We aimed to assess if addition of avelumab …

Surgery for locoregionally advanced head and neck squamous cell carcinoma (HNSCC)
results in 30‒50% five-year overall survival. In IMCISION (NCT03003637), a non …

Targeted immunotherapy has improved patient survival in head and neck squamous cell
carcinoma (HNSCC), but less than 20% of patients produce a durable response to these …

Background Pembrolizumab is active in head and neck squamous cell carcinoma (HNSCC),
with programmed cell death ligand 1 (PD-L1) expression associated with improved …

Head and neck squamous cell carcinoma (HNSCC) is characterized by complex relations
between stromal, epithelial, and immune cells within the tumor microenvironment (TME). To …

Head and neck cancers are a heterogeneous collection of malignancies of the upper
aerodigestive tract, salivary glands and thyroid. In this Review, we primarily focus on the …

Summary Background Pembrolizumab (PD-1 inhibitor) and cetuximab (EGFR inhibitor) are
active as single agents and in combination with cytotoxic chemotherapy for recurrent or …

Background There are few effective treatment options for patients with recurrent or
metastatic head-and-neck squamous cell carcinoma. Pembrolizumab showed antitumour …